Tranilast/allopurinol - Nuon Therapeutics

Drug Profile

Tranilast/allopurinol - Nuon Therapeutics

Alternative Names: NU-1618

Latest Information Update: 12 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nuon Therapeutics
  • Class Anthranilic acids; Antigouts; Antirheumatics; Purines; Small molecules; Uricosurics
  • Mechanism of Action Immunomodulators; SLC2A9 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Gout; Hyperuricaemia

Most Recent Events

  • 05 Jan 2011 Nuon Therapeutics completes the phase II TAnGO trial in Gout in USA (NCT01109121)
  • 23 Jun 2010 Efficacy and adverse events data from clinical trials in Hyperuricaemia released by Nuon Therapeutics
  • 23 Jun 2010 Pharmacodynamics data from a preclinical trial in Gout released by Nuon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top